From 2003 to 2016 Dr Moeller also served as Chairman of FIND (Foundation for Innovative New Diagnostics), a PDP with the Bill and Melinda Gates Foundation. In May 2018 Dr Moeller resigned from the Board of Directors of Morphosys AG after 19 years of Service as Chairman. Today he serves on the Board of
4Sigma GmbH,Germany (Chairman); (Healthcare Services)
Sphingotec GmbH, Germany (ViceChairman)
4teen4 GmbH, Germany, (Director)
DIADEM DX, Italy, (Chairman)
Dr Möller cofounded Adrenomed AG, a Biopharmaceutical company, served as Vice Chairman, from 12/17 to 8/19 as CEO and since 12/19 as Director. From 1975-1998, Dr. Moeller held several senior level positions in Germany, Japan, USA and the Netherlands with Boehringer Mannheim, including: Head of R&D Diagnostics; President of Decentralized Diagnostics; CEO of Boehringer Mannheim Therapeutics; and Chief Technology Officer of Corange, the holding company of Boehringer Mannheim. In 1995 he became CEO of the worldwide Boehringer Mannheim Group, which generated sales of >$4 billion in 1997. Following the sale of Boehringer Mannheim Group to Roche in 1998, Dr. Moeller was named Head of Global Development and Strategic Marketing Pharmaceuticals, as well as a member of Roche’s Executive Committee. Dr. Moeller left Roche in December 1998. Dr. Moeller received his Ph.D. in Physical Chemistry from the University of Kiel, Germany. He is married with 2 children.
Prior to Sofinnova, Henrijette was part of the team that founded Novo Seeds in 2007, and as an Investment Director, she was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris). Henrijette holds a combined Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.